Results 261 to 270 of about 314,623 (355)

An unusual variant of May-Thurner syndrome leading to deep venous thrombosis: a case report. [PDF]

AME Case Rep
Mulayamkuzhiyil J, Joseph J, Ahmad Z, London J, James SA, Mehta P, Gkotsis G.   +6 more
europepmc   +1 more source

BALANCING RISK AND BENEFIT: DEEP VENOUS THROMBOSIS SURVEILLANCE IN LUNG TRANSPLANT RECIPIENTS [PDF]

LARA JONES, Jonathan Gelfond, HOLLY L KEYT   +2 more
openalex   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Predictive Value of Combined CRP and INR for Intracranial Hypertension in Cerebral Venous Thrombosis. [PDF]

Immun Inflamm Dis
Yan J, Lu M, Huang Z, Xu Y, Cao Y, Ni J, Zhang X.   +6 more
europepmc   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Cerebral Venous Thrombosis Following Periocular Filler Injection-A Case Report and Review of Literature. [PDF]

Case Rep Neurol Med
Asgari R, Bazzazan M, Jafari F, Mozhdehipanah H.   +3 more
europepmc   +1 more source

Association of genetic variants of hemostasis system genes with a burdened obstetric-gynecological history in women and venous thrombosis during gestation

O. A. Perevesentsev, Ilgar Mamedov
openalex   +2 more sources

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga, J. L. Artola‐Igarza, N. Martinez‐Peña, I. Arevalo‐Ortega, J. Rodriguez‐Blandon, G. Cancho‐Galan, R. Izu‐Belloso   +6 more
wiley   +1 more source

Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism. [PDF]

Blood
Sang Y, Menegatti M, Brody JA, Wiggins KL, Cooley BC, Kapfer KN, Kangro K, de Laat B, Peyvandi F, Flick MJ, Smith NL, Shapiro AD, Wolberg AS.   +12 more
europepmc   +1 more source

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu, Wen‐Juan Wang, Ting‐Ting Zhang, Qi‐Chong Yang, Haliminai Dilimulati, Song‐Tao An   +5 more
wiley   +1 more source